PMID- 11459901
OWN - NLM
STAT- MEDLINE
DCOM- 20010927
LR  - 20220408
IS  - 0022-3050 (Print)
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
VI  - 71
IP  - 2
DP  - 2001 Aug
TI  - Intravenous immune globulins in patients with Guillain-Barre syndrome and 
      contraindications to plasma exchange: 3 days versus 6 days.
PG  - 235-8
AB  - Plasma exchange is contraindicated in 10 to 20% of patients with Guillain-Barre 
      syndrome (GBS). The optimal schedule for intravenous immune globulin (IVIg) 
      therapy has not yet been established in these patients. The objective was to 
      compare the efficacy and safety of two IVIg treatment durations in patients with 
      GBS with contraindications for plasma exchange. In this randomised, double blind, 
      multicentre phase II trial conducted in seven French centres, patients with GBS 
      with severe haemostasis, unstable haemodynamics, or uncontrolled sepsis were 
      randomly assigned to 0.4 g/kg/day IVIg for 3 or 6 days. The primary outcome 
      measure was the time needed to regain the ability to walk with assistance. Thirty 
      nine patients were included from March 1994 to May 1997, 21 in the 3 day group 
      and 18 in the 6 day group. Time to walking with assistance was non-significantly 
      shorter in the 6 day group (84 (23-121) v 131 days (51-210), p=0.08); the 
      difference was significant in ventilated patients (86 days (13-151) in the 6 day 
      group v 152 days (54-332) in the 3 day group; p=0.04). The prevalence and 
      severity of IVIg related adverse effects were comparable between the two groups. 
      In conclusion, in patients with GBS and contraindications for plasma exchange, 
      especially those who need ventilatory assistance, IVIg (0.4 g/kg/day) may be more 
      beneficial when given for 6 days rather than 3 days.
FAU - Raphael, J C
AU  - Raphael JC
AD  - Hopital Raymond Poincare, Service de Reanimation Medicale, 104 Boulevard Raymond 
      Poincare, 92380 Garches, France.
FAU - Chevret, S
AU  - Chevret S
FAU - Harboun, M
AU  - Harboun M
FAU - Jars-Guincestre, M C
AU  - Jars-Guincestre MC
CN  - French Guillain-Barre Syndrome Cooperative Group
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Aged
MH  - Contraindications
MH  - Double-Blind Method
MH  - Female
MH  - Guillain-Barre Syndrome/*drug therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/*adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Outcome Assessment, Health Care
MH  - Pilot Projects
MH  - *Plasma Exchange
MH  - Random Allocation
MH  - Sample Size
MH  - Time Factors
PMC - PMC1737513
EDAT- 2001/07/19 10:00
MHDA- 2001/09/28 10:01
PMCR- 2004/08/01
CRDT- 2001/07/19 10:00
PHST- 2001/07/19 10:00 [pubmed]
PHST- 2001/09/28 10:01 [medline]
PHST- 2001/07/19 10:00 [entrez]
PHST- 2004/08/01 00:00 [pmc-release]
AID - 10.1136/jnnp.71.2.235 [doi]
PST - ppublish
SO  - J Neurol Neurosurg Psychiatry. 2001 Aug;71(2):235-8. doi: 10.1136/jnnp.71.2.235.